American Society of Clinical Oncology

SHERPA: White

People

  1. Hudis
    Hudis
  2. Seidman
    Seidman
  3. Norton
    Norton
  4. D'Andrea-Carlino
    D'Andrea-Carlino
  5. Lake
    Lake
  6. Sklarin
    Sklarin
  7. Fornier
    Fornier
  8. Traina
    Traina
  9. Panageas
    Panageas
  10. Bach
    Bach

Groups

  1. Breast Medicine Service (41)
  2. Department of Medicine (41)
  3. Solid Tumor Oncology Division (41)
  4. Survivorship Research (41)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (27)
  6. Epidemiology and Biostatistics (14)
  7. Biostatistics Service (13)
  8. Radiology, Department of (12)
  9. Behavioral Sciences Service (10)
  10. Body Imaging Service (10)
Search Within
  1. "Andrew Seidman"
  2. "Clifford Hudis"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (20)
Groups
  1. Breast Medicine Service (41)
  2. Department of Medicine (41)
  3. Solid Tumor Oncology Division (41)
  4. Survivorship Research (41)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (27)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Andrew Seidman (41)
  2. Clifford Hudis (41)
  3. Larry Norton (27)
  4. Diana Lake (10)
  5. Gabriella D'Andrea-Carlino (10)
  6. Teresa Gilewski (10)

More People

Years
  1. 2014 (2)
  2. 2013 (1)
  3. 2012 (2)
  4. 2011 (1)
  5. 2010 (3)
  6. 2009 (2)

More Years

Publications
  1. Journal of Clinical Oncology (41)

Results (41)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC)
    Meeting Abstract

    Traina, T. A.; Kaufman, P. A.; Cadoo, K. A.; Hudis, C. A.; Chang, C.; Berrak, E.; Song, J.; Cox, D.; Seidman, A. D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Morikawa, A.; Diab, A.; Patil, S.; Forte, V.; Blum, B.; Young, R. J.; Beal, K.; Hudis, C.; Seidman, A. D.; Mcarthur, H. L.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II, single-arm, feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early-stage breast cancer (EBC)
    Meeting Abstract

    Traina, T. A.; Hudis, C.; Lehman, R.; Rege, J.; Wang, W.; Cox, D.; Seidman, A. D.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer
    Meeting Abstract

    Seidman, A. D.; Schwartzberg, L. S.; O'Shaughnessy, J.; D'Andrea, G.; Rubin, P.; Katz, S.; Danesi, H.; Itri, L.; Hudis, C.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study
    Meeting Abstract

    Murphy, C.; Mallam, D.; Stein, S.; Patil, S.; Howard, J.; Sklarin, N. T.; Gemignani, M.; Hudis, C.; Seidman, A. D.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Journal Article

    Traina, T. A.; Rugo, H. S.; Caravelli, J. F.; Patil, S.; Yeh, B.; Melisko, M. E.; Park, J. W.; Geneus, S.; Paulson, M.; Grothusen, J.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer
    Meeting Abstract

    Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save